3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Neoplasm Metastasis
1
Liver Cirrhosis
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Leucovorin
3
Irinotecan
3
Capecitabine
3
Trastuzumab
2
Taxes
2
Oxaliplatin
2
Fluorouracil
2
zenocutuzumab
1
veliparib
1
tislelizumab
1
tipifarnib
1
tegafur-gimeracil-oteracil
1
spartalizumab
1
erythromycin propionate-N-acetylcysteinate
1
entinostat
1
atezolizumab
1
Transurethral Resection of Prostate
1
Surveys and Questionnaires
1
Radiotherapy
1
Radiosurgery
1
Quality of Life
1
Polymerase Chain Reaction
1
Poly(ADP-ribose) Polymerase Inhibitors
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Molecular Diagnostic Techniques
1
Mebendazole
1
Magnetic Resonance Spectroscopy
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Unknown Primary
×
Mebendazole
×
Gastrointestinal
×
Clear all
NCT03628079
2020-01-22
RepoMeb
Repos Pharma
Phase 1/2
Terminated
11 enrolled